NewslettersMammary Cell NewsCeritinib Is a Novel Triple Negative Breast Cancer Therapeutic AgentBy Bob - June 30, 20220209Combination therapy of Ceritinib and Enzalutamide were investigated using androgen receptor positive breast cancer mouse xenograft models.[Molecular Cancer]Full ArticlePress Release